Protease inhibitor-sparing simplified maintenance therapy: A need for perspective

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 303-305

  Bucher, Heiner C ^a,b   Young, James ^a   Battegay, Manuel ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antiretroviral therapy; Metabolic toxicity; Treatment failure

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; GLUCOSE; HYDROXYUREA; LACTIC ACID; LOPINAVIR; NEVIRAPINE; NEW DRUG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY LIVER; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPOHYPERTROPHY; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; META ANALYSIS; METABOLIC DISORDER; MYOPATHY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; TREATMENT FAILURE; VIREMIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL PROTOCOLS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 4444330606     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh379     Document Type: Article

References (16)

1. Carr, A., Samaras, K., Burton, S. et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-8.
2. Martinez, E., Mocroft, A., Garcia-Viejo, M. A. et al. (2001). Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357, 592-8.
3. Carr, A., Miller, J., Law, M. et al. (2000). A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-1732.
4. Fontas, E., van Leth, F., Sabin, C. A. et al. (2004). Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Journal of Infectious Diseases 189, 1056-74.
5. Hirsch, H. H. & Battegay, M. (2002). Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection 30, 293-8.
6. Carr, A. (2003). HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17, Suppl. 1, S141-8.
7. Friis-Moller, N., Sabin, C. A., Weber, R. et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349, 1993-2003.
8. Bucher, H. C., Kofler, A., Nuesch, R. et al. (2003). Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 17, 2451-9.
9. Martinez, E., Arnaiz, J. A., Podzamczer, D. et al. (2003). Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. New England Journal of Medicine 349, 1036-46.
10. Phillips, A. N., Ledergerber, B., Horban, A. et al. (2004). Rate of viral rebound according to specific drugs in the regimen in 1951 patients who have attained viral load <50 copies/ml. In Abstracts of the Fifteenth International AIDS Conference July 11-16. Bangkok, Thailand, 2004, Abstract TuPeb4542.
11. Carr, A., Hudson, J., Chuah, J. et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15, 1811-22.
12. Ruiz, L., Negredo, E., Domingo, P. et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes 27, 229-36.
13. Negredo, E., Cruz, L., Paredes, R. et al. (2002). Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases 34, 504-10.
14. Martinez, E., Romeu, J., Garcia-Viejo, M. A. et al. (2001). An open randomized study on the replacement of HIV-1 protease inhibitors in chronically suppressed HIV-1-infected patients with lipodystrophy. In Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA. Abstract 668. http://www.retroconference.org/2001/.
15. John, M., McKinnon, E. J., James, I. R. et al. (2003). Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndrome 33, 29-33.
16. Carr, A., Workman, C., Smith, D. E. et al. (2002). Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Journal of the American Medical Association 288, 207-15.